SG11202011554PA - Composition comprising antisense oligonucleotide and use thereof for treatment of duchenne muscular dystrophy - Google Patents
Composition comprising antisense oligonucleotide and use thereof for treatment of duchenne muscular dystrophyInfo
- Publication number
- SG11202011554PA SG11202011554PA SG11202011554PA SG11202011554PA SG11202011554PA SG 11202011554P A SG11202011554P A SG 11202011554PA SG 11202011554P A SG11202011554P A SG 11202011554PA SG 11202011554P A SG11202011554P A SG 11202011554PA SG 11202011554P A SG11202011554P A SG 11202011554PA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- composition
- antisense oligonucleotide
- muscular dystrophy
- duchenne muscular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690270P | 2018-06-26 | 2018-06-26 | |
| US201862739386P | 2018-10-01 | 2018-10-01 | |
| PCT/JP2019/026393 WO2020004675A1 (ja) | 2018-06-26 | 2019-06-26 | アンチセンスオリゴヌクレオチドを含有する組成物およびデュシェンヌ型筋ジストロフィーの治療へのその使用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202011554PA true SG11202011554PA (en) | 2020-12-30 |
Family
ID=68987235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202011554PA SG11202011554PA (en) | 2018-06-26 | 2019-06-26 | Composition comprising antisense oligonucleotide and use thereof for treatment of duchenne muscular dystrophy |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20210261963A1 (zh) |
| EP (1) | EP3815696A4 (zh) |
| JP (2) | JP7345466B2 (zh) |
| KR (1) | KR20210023988A (zh) |
| CN (1) | CN112399849A (zh) |
| AU (1) | AU2019293687A1 (zh) |
| BR (1) | BR112020026542A2 (zh) |
| CA (1) | CA3101321A1 (zh) |
| CL (1) | CL2020003367A1 (zh) |
| CO (1) | CO2020015685A2 (zh) |
| EC (1) | ECSP20083454A (zh) |
| IL (1) | IL279692A (zh) |
| MX (1) | MX2020013880A (zh) |
| PE (1) | PE20210630A1 (zh) |
| PH (1) | PH12020552078A1 (zh) |
| SG (1) | SG11202011554PA (zh) |
| TW (1) | TW202035692A (zh) |
| WO (1) | WO2020004675A1 (zh) |
| ZA (1) | ZA202007682B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022232478A1 (en) | 2021-04-30 | 2022-11-03 | Sarepta Therapeutics, Inc. | Treatment methods for muscular dystrophy |
| WO2023178230A1 (en) | 2022-03-17 | 2023-09-21 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer conjugates |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0506830B1 (en) | 1989-12-20 | 2005-12-14 | Avi Biopharma, Inc. | Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages |
| ES2566628T3 (es) | 2002-11-25 | 2016-04-14 | Masafumi Matsuo | Fármacos de ácido nucleico ENA que modifican el corte y empalme en precursores de ARNm |
| EP4047096A1 (en) | 2004-06-28 | 2022-08-24 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| WO2006038608A1 (ja) | 2004-10-05 | 2006-04-13 | Nippon Shinyaku Co., Ltd. | オリゴ二本鎖ｒｎａ及び医薬組成物 |
| CA2609032A1 (en) | 2005-05-30 | 2006-12-07 | Nippon Shinyaku Co., Ltd. | Method for producing a nucleic-acid-containing complex preparation |
| MX2010004955A (es) | 2007-11-15 | 2010-06-30 | Avi Biopharma Inc | Metodo de sintesis de oligomeros de morfolina. |
| US8084601B2 (en) * | 2008-09-11 | 2011-12-27 | Royal Holloway And Bedford New College Royal Holloway, University Of London | Oligomers |
| EP3428278A1 (en) | 2008-10-24 | 2019-01-16 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for dmd |
| TWI541024B (zh) * | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| EP4043039A1 (en) * | 2012-01-27 | 2022-08-17 | BioMarin Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
| CA2903872A1 (en) * | 2013-03-14 | 2014-09-25 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| NZ631289A (en) | 2013-03-15 | 2017-08-25 | Sarepta Therapeutics Inc | Improved compositions for treating muscular dystrophy |
| EP3015467A4 (en) * | 2013-05-24 | 2016-11-02 | Ajinomoto Kk | PROCESS FOR THE PRODUCTION OF MORPHOLINO-OLIGONUCLEOTIDE |
| EP3355892A4 (en) * | 2015-09-30 | 2019-05-22 | Sarepta Therapeutics, Inc. | METHODS OF TREATING MUSCLE DYSTROPHY |
| FR3044926B1 (fr) * | 2015-12-09 | 2020-01-31 | Genethon | Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine |
-
2019
- 2019-06-26 KR KR1020217001037A patent/KR20210023988A/ko unknown
- 2019-06-26 AU AU2019293687A patent/AU2019293687A1/en active Pending
- 2019-06-26 CA CA3101321A patent/CA3101321A1/en active Pending
- 2019-06-26 CN CN201980043482.XA patent/CN112399849A/zh active Pending
- 2019-06-26 SG SG11202011554PA patent/SG11202011554PA/en unknown
- 2019-06-26 BR BR112020026542-0A patent/BR112020026542A2/pt unknown
- 2019-06-26 MX MX2020013880A patent/MX2020013880A/es unknown
- 2019-06-26 TW TW108122381A patent/TW202035692A/zh unknown
- 2019-06-26 JP JP2020527712A patent/JP7345466B2/ja active Active
- 2019-06-26 US US17/253,760 patent/US20210261963A1/en not_active Abandoned
- 2019-06-26 WO PCT/JP2019/026393 patent/WO2020004675A1/ja active Application Filing
- 2019-06-26 EP EP19826094.5A patent/EP3815696A4/en active Pending
- 2019-06-26 PE PE2020002157A patent/PE20210630A1/es unknown
-
2020
- 2020-12-02 PH PH12020552078A patent/PH12020552078A1/en unknown
- 2020-12-09 ZA ZA2020/07682A patent/ZA202007682B/en unknown
- 2020-12-14 CO CONC2020/0015685A patent/CO2020015685A2/es unknown
- 2020-12-22 IL IL279692A patent/IL279692A/en unknown
- 2020-12-23 EC ECSENADI202083454A patent/ECSP20083454A/es unknown
- 2020-12-23 CL CL2020003367A patent/CL2020003367A1/es unknown
-
2023
- 2023-09-05 JP JP2023143451A patent/JP2023171731A/ja active Pending
- 2023-11-08 US US18/504,781 patent/US20240158792A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL279692A (en) | 2021-03-01 |
| ECSP20083454A (es) | 2021-01-29 |
| JP2023171731A (ja) | 2023-12-05 |
| MX2020013880A (es) | 2021-03-09 |
| US20210261963A1 (en) | 2021-08-26 |
| PH12020552078A1 (en) | 2021-05-31 |
| TW202035692A (zh) | 2020-10-01 |
| US20240158792A1 (en) | 2024-05-16 |
| AU2019293687A1 (en) | 2021-01-07 |
| EP3815696A4 (en) | 2022-11-30 |
| JPWO2020004675A1 (ja) | 2021-07-15 |
| JP7345466B2 (ja) | 2023-09-15 |
| EP3815696A1 (en) | 2021-05-05 |
| ZA202007682B (en) | 2024-04-24 |
| KR20210023988A (ko) | 2021-03-04 |
| CL2020003367A1 (es) | 2021-05-24 |
| BR112020026542A2 (pt) | 2021-04-06 |
| WO2020004675A1 (ja) | 2020-01-02 |
| CA3101321A1 (en) | 2020-01-02 |
| CO2020015685A2 (es) | 2021-04-30 |
| CN112399849A (zh) | 2021-02-23 |
| PE20210630A1 (es) | 2021-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2610100B (en) | Antisense oligomers for treatment of non-sense mediated RNA decay based conditions and diseases | |
| IL291933A (en) | Compositions of oligonucleotides and methods of using them | |
| IL277889A (en) | Preparations of oligonucleotides and methods of using them | |
| SG11202111387YA (en) | Oligonucleotide compositions and methods of use thereof | |
| SG11202010131QA (en) | Oligonucleotide compositions and methods of use thereof | |
| EP4037695A4 (en) | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | |
| SG11202111386UA (en) | Oligonucleotide compositions and methods of use thereof | |
| SI3159409T1 (sl) | Protismiselna nukleinska kislina za uporabo pri zdravljenju Duchennove mišične distrofije | |
| MA45819A (fr) | Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés | |
| EP3655535A4 (en) | ANTISEN OLIGONUCLEOTIDES THAT BIND TO HUMAN DYSTROPHINE PRE-RNAM EXON 51 | |
| HK1257247A1 (zh) | 用於預防及治療杜興氏肌肉營養不良症的方法和組合物 | |
| IL269735A (en) | Antisense oligonucleotides for the treatment of Stragradt disease | |
| IL279692A (en) | A preparation containing antisense oligonucleotides and their uses for the treatment of Duchenne syndrome | |
| IL288259A (en) | Modified Gapmer Oligonucleotides and Methods of Use | |
| IL257296B (en) | Methods of sedation and intravenous vehicle for use during critical care | |
| IL272036A (en) | Methods and compositions for treating pain using capsaicin | |
| IL304674A (en) | Reagents for the treatment of oculopharyngeal muscular dystrophy (opmd) and their uses | |
| GB201714027D0 (en) | Antisense oligonucleotides for the treatment of huntington's disease | |
| IL286872A (en) | Antisense oligonucleotides for the treatment of usher syndrome | |
| IL277238A (en) | Modified oligonucleotides for use in the treatment of tauopathy | |
| ZA201807589B (en) | Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof | |
| ZA201908276B (en) | Charge-tagged nucleotides and methods of use thereof | |
| IL262013A (en) | Composition for the treatment of duchenne muscular dystrophy | |
| GB201612920D0 (en) | Composition for the treatment of Duchenne Muscular Dystrophy | |
| GB201605380D0 (en) | Composition for the treatment of duchenne muscular dystrophy |